US OptionsDetailed Quotes
CABA250516C1500
- 0.06
- -0.06-50.00%
15min DelayClose May 6 15:55 ET
0.06High0.06Low
0.06Open0.12Pre Close10 Volume281 Open Interest1.50Strike Price60.00Turnover275.82%IV35.65%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier10DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type0.3579Delta0.7223Gamma11.50Leverage Ratio-0.0102Theta0.0001Rho4.12Eff Leverage0.0007Vega
Cabaletta Bio Stock Discussion
“Title: Clinical and Translational Studies of Rese-cel (an anti-CD19 CAR T Therapy) in Myositis, SLE, and Systemic Sclerosis: RESET Phase I/II Trials
Date and Time: Saturday, February 22, 2025, 10:15 a.m. – 10:30 a.m. CET
*Additional information can be accessed on the website of each scientific meeting. Presentation materials will be made available on the Posters & Publications section of the Company's website following each event.
About rese-cel (formerly referred to ...
The latest clinical data from Cabaletta Bio's rese-cel program represents a significant milestone in autoimmune disease treatment. The achievement of DORIS remission in 3 out of 4 SLE patients, complete renal response in lupus nephritis, and sustained improvement in dermatomyositis - all while discontinuing immunosuppressants - suggests a potentially transformative therapeutic approach.
The confirmed deep B cell depletion, both in circulation and ...
Breakthrough Clinical Results: Rese-cel Treatment Achieves Remission in Lupus Patients, Shows Promise Across Autoimmune Disorders
Revolutionary Autoimmune Treatment Success: Patients Achieve Complete Remission, Stop All Medications
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses Across Multiple Indications With Rese-Cel at February Scientific Meetings
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
Tuesday, 18th February at 7:00 am
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued all immunosu...
No comment yet